Expanding the Horizons Of Proton Beam Therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Cancer Letter recently published information regarding proton therapy facilities in the U.S., highlighting a contention that 85 percent of patients treated with protons have prostate cancer, the logical implication of which would be that this important resource is utilized minimally for other cancers. In this response, we wish to correct this erroneous impression and also wish to highlight the direction that this technology is moving in.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Minesh P. Mehta
Professor of radiation oncology, University of Maryland School of Medicine; Medical director, Maryland Proton Treatment Center
Katja Langen
Associate professor of radiation oncology, University of Maryland School of Medicine;
Associate chief of proton physics, Maryland Proton Treatment Center
William F. Regine
Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology, University of Maryland School of Medicine; Executive director, Maryland Proton Treatment Center

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Minesh P. Mehta
Professor of radiation oncology, University of Maryland School of Medicine; Medical director, Maryland Proton Treatment Center
Katja Langen
Associate professor of radiation oncology, University of Maryland School of Medicine;
Associate chief of proton physics, Maryland Proton Treatment Center
William F. Regine
Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology, University of Maryland School of Medicine; Executive director, Maryland Proton Treatment Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login